Cancer Biology and Therapeutics, Centre de Recherche Saint-Antoine, INSERM U938, Institut Universitaire de Cancérologie, Faculty of Medicine Pierre and Marie Curie (UPMC), Sorbonne Universities, Paris, France.
Clinical Research, Diagnostica Stago, Gennevilliers, France.
Int J Oncol. 2017 Dec;51(6):1793-1800. doi: 10.3892/ijo.2017.4170. Epub 2017 Oct 20.
Hypercoagulablity is a common alteration of blood coagulation in cancer patients. However, the procoagulant activity of cancer cells is not sufficient to induce hypercoagulability. The present study was aimed to identify the mechanism with which hypercoagulabilty is produced in the presence of cancer cells. We focused on the analysis of the procoagulant elements carried by cancer cell-derived microparticles (CaCe-dMP) and we evaluated the impact of microparticles associated with the cancer cells from which they stem on thrombin generation. CaCe-dMP from the cancer cells were isolated from the conditioned medium and analyzed for tissue factor (TF) and procoagulant phospholipid expression. Thrombin generation of normal plasma was assessed by the Thrombinoscope (CAT®) in the presence or absence of pancreas adeno-carcinoma cells (BXPC3) or breast cancer MCF7 cells supplemented with the respective CaCe-dMP. Both BXPC3 and MCF7 cells express abundant amounts of active TF. Phosphatidylserine was identified on the surface of CaCe-dMP, unlike the cancer cells themselves. The expression of TFa by the microparticles was significantly higher to that observed on the cancer cells. Culture of the cancer cells with their microparticles resulted in thrombin generation significantly higher as compared to the upper normal limit. In conclusion, cancer cells 'enrich' the microenvironment with procoagulant elements, especially procoagulant micro-particles which express TF and procoagulant phospholipids. The association of cancer cells with procoagulant microparticles is necessary for a state of hypercoagulability, at the level of the tumoral microenvironment. The intensity of the hypercoagulability depends on the histological type of the cancer cells.
高凝状态是癌症患者凝血功能常见的改变。然而,癌细胞的促凝活性不足以引起高凝状态。本研究旨在确定在存在癌细胞的情况下产生高凝状态的机制。我们专注于分析由癌细胞衍生的微颗粒(CaCe-dMP)携带的促凝因子,并评估与它们起源的癌细胞相关的微颗粒对凝血酶生成的影响。从条件培养基中分离出癌细胞衍生的微颗粒,并分析组织因子(TF)和促凝磷脂的表达。正常血浆的凝血酶生成通过凝血酶谱仪(CAT®)在胰腺腺癌细胞(BXPC3)或乳腺癌 MCF7 细胞存在或不存在的情况下进行评估,并用相应的 CaCe-dMP 进行补充。BXPC3 和 MCF7 细胞均表达大量活性 TF。与癌细胞本身不同,CaCe-dMP 表面存在磷脂酰丝氨酸。微粒表面 TFa 的表达明显高于癌细胞上的表达。与微颗粒共培养的癌细胞导致凝血酶生成明显高于正常上限。总之,癌细胞通过表达 TF 和促凝磷脂的促凝微颗粒“丰富”微环境中的促凝因子。癌细胞与促凝微颗粒的关联是肿瘤微环境中高凝状态的必要条件。高凝状态的强度取决于癌细胞的组织学类型。